

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
300.1005CON

SERIAL NO.: 10795,411

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): CHEN et al.

FILING DATE: March 9, 2004

GROUP: 1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
AB						

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MY	AC	Approval letter from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 000, October 13, 2000
MY	AD	Approved Label for Glucophage/Glucophage XR, NDA 21-202, Supplement 000, October 13, 2000
MY	AE	Approval letter on labeling revision from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 003, January 8, 2002
MY	AF	Approval letter on formulation revision from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 008, April 11, 2003
MY	AG	Approval letter on labeling revision from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 011, March 19, 2004
MY	AH	Approval letter on labeling revision from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 013, March 19, 2004
MY	AI	Approval letter on labeling revision from Center for Drug Evaluation and Research to Bristol-Myers Squibb Company on NDA 21-202, Supplement 001, April 19, 2001
MY	AJ	Approved Label For Glucophage/Glucophage XR NDA 21-202, Supplement 013, March 19, 2004
MY	AK	Approved Label for Glucophage/Glucophage XR NDA 21-202, Supplement 011, March 19, 2004
MY	AL	Approved Label for Glucophage/Glucophage XR NDA 21-201, Supplement 008, labeling revision, April 11, 2003
	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
	AS	

EXAMINER /Micah Paul Young/

DATE CONSIDERED 07/12/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 300.1005CON		SERIAL NO.: 10/796,411							
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)						APPLICANT(S): CHEN et al.									
						FILING DATE: March 9, 2004		GROUP: 1615							
U.S. PATENT DOCUMENTS															
*EXAMINER INITIAL	BA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
MY	BA	5	9	1	4	3	2	6	06/22/99	McCarty et al.	514	188			
MY	BB	6	1	1	7	4	5	1	09/12/00	Kumar	424	465			
MY	BG	5	1	0	0	6	6	5	03/31/92	Hyon, et al.	424	426			
MY	BD	5	8	3	7	3	7	9	11/17/98	Chen et al.	424	465			
MY	BE	6	0	5	6	9	7	7	05/02/00	Bhagwat et al.	424	488			
MY	BF	20	06	00	34	9	2	2	02/16/06	Cheng et al.					
MY	BG	20	06	00	08	5	7	5	01/12/06	Chen et al.					
MY	BH	20	06	00	08	5	2	4	01/12/06	Chen et al.					
MY	BI	20	06	00	08	5	2	3	01/12/06	Chen et al.					
MY	BJ	20	06	00	08	5	2	6	01/12/06	Chen et al.					
MY	BK	20	04	00	52	8	4	8	03/18/04	Cheng et al.					
MY	BF	20	01	00	24	6	5	9	09/27/01	Chen et al.					
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
														YES	NO
MY	BM	2	2	5	1	4	3	0	02/28/00	CA	A61K	31/44			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
MY	BN	E.K. Kastrup: "Anidiabetic Agents," DRUG FACTS AND COMPARISONS, 1999, St. Louis, pp 635-642													
MY	BO	Physicians' Desk Reference, "Glucophage XR," 56 <sup>th</sup> edition, pages 1080-1086													
MY	BP	Physicians' Desk Reference, "Glucophage," 52 <sup>nd</sup> edition, pages 795-800													
MY	BQ	STN Registry Search for Metformin													
	BR														
	BS														
EXAMINER /Micah Paul Young/										DATE CONSIDERED 07/12/2006					
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>															